Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects
Summary
This is a single-center, placebo-controlled, randomized, ascending dose, double-blind study. This study will be evaluating ascending doses of 50, 100, 200, and 400 mg of E6007. This study consists of 5 steps, 1 to 5. In steps 1 to 4 (at ascending doses of 50, 100, 200, and 400 mg), subjects will be randomly assigned in a 6:2 ratio (E6007: placebo) to receive single dose of the study drug under fasted condition. Following 3 days of washout period, subject will receive the study drug once daily for 7 days starting on the fifth day from the single dose administration. For step 3 (200 mg), subjects will subsequently have at least 17 days of washout period before being escalated to step 5 (200 mg) to receive single dose of E6007 under fed condition, to evaluate food effect of the study drug.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-07
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E6007 | Unknown | 50 mg | Oral |
| Subject | E6007 | Unknown | 100 mg | Oral |
| Subject | E6007 | Unknown | 200 mg | Oral |
| Subject | E6007 | Unknown | 400 mg | Oral |
Indications
No indication recorded.